Scarica l'app Stockscreener
134.22
0.56%
-0.525
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
Cantor Fitzgerald reiterates Insmed stock rating on Brensupri sales outlook By Investing.com - Investing.com Canada
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo Finance
Insmed Inc (INSM) Institutional Confidence - TradingKey
Insmed Inc (INSM) Cash Flow - TradingKey
Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insmed Inc (INSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Insmed Inc (INSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Insmed Inc (INSM) Income Statement - TradingKey
INSM|Insmed Inc|Price:104.760|Chg%:+0.030 - TradingKey
Insmed Incorporated Revenue Breakdown – NASDAQ:INSM - TradingView
Insmed chair and CEO William Lewis sells over $1.1m in company stock - Investing.com Australia
INSM|Insmed Inc|Price:106.920|Chg%:-0.490 - TradingKey
Form 4 Insmed Inc For: 24 July By Investing.com - Investing.com Canada
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Insmed Incorporated Revenue Breakdown – LSE:0JAV - TradingView
Insmed Inc. CEO William Lewis Executes Key Stock Option Acquisitions and Share Sales - Kalkine Media
Insmed (INSM) CEO trades 10,700 shares after option exercise - Stock Titan
Concerns Over the Pace of its Brinsupri’s Launch Hurt Insmed (INSM) - Yahoo Finance
Insmed and Ty Pennington team up - WFLA
Form 144 INSMED INC For: 24 July - Investing.com UK
Form 144 INSMED INC For: 24 July By Investing.com - Investing.com South Africa
Insmed Inc (INSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INSMED INC (INSM.MX) Q1 FY2026 earnings call transcript - Yahoo Finance
Insmed (INSM) insider William Lewis plans 10,700-share stock sale - Stock Titan
William Haggerty Joins Insmed Incorporated as Senior Director of People Operations - hrtoday.in
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), TransMedics Group (TMDX) and Hims & Hers Health (HIMS) - The Globe and Mail
Insmed's second-quarter business update will be webcast Aug. 6 - Stock Titan
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Guggenheim Reaffirms Their Buy Rating on Insmed (INSM) - The Globe and Mail
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
JPMorgan Chase & Co. (INSM) reports 10.37M Insmed shares, a 4.7% stake - Stock Titan
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $207 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
INSM Initiated Coverage by BMO Capital -- Price Target Announced at $192 - GuruFocus
BMO Capital Initiates Insmed at Outperform With $192 Price Target - marketscreener.com
Is Insmed (INSM) Priced Too Richly For Its Phase 3 Progress? - Yahoo Finance
Insmed (INSM) Following TPIP 12 Month Data, Does The Valuation Still Stack Up - Yahoo Finance
BMO initiates Insmed stock with outperform rating on respiratory franchise potential - Investing.com Nigeria
Insmed Announces Positive 12-Month Data from OLE Study of Inhalation Solution for Pulmonary Arterial Hypertension - dicardiology.com
Positive 12‑Month TPIP PAH Data Could Be A Game Changer For Insmed (INSM) - Yahoo Finance
Buy Insmed for a double, this analyst says - Cantech Letter
Investors’ Concerns Hurt Insmed Incorporated (INSM) Despite Better-Than-Expected Results - Yahoo Finance
Insmed stock price target maintained at $220 by H.C. Wainwright - Investing.com Canada
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3 - webull.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $161 to $237 - Moomoo
Open-label extension drives home benefits of Insmed’s PAH therapy - BioWorld News
Stifel Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $200 - Moomoo
Insmed stock price target maintained at $200 by Stifel on trial data - Investing.com Canada
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning - Benzinga
INSM: TPIP sustained robust efficacy and safety at 12 months, with 65% reaching refined low-risk status - TradingView
Insmed (INSM) Reports Promising 12-Month Results for TPIP in PAH Patients - GuruFocus
Insmed's TPIP Shows Durable PAH Benefits in 12-Month Study - Yahoo Finance
INSM: TPIP sustained best-in-class efficacy and safety at 12 months, with 65% reaching low-risk status - TradingView
Insmed Says Treprostinil Shows Sustained Benefit to Pulmonary Arterial Hypertension Patients - Moomoo
0.85%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):